Palisade Bio is a clinical-stage biopharmaceutical company that develops therapies for acute and chronic gastrointestinal complications.
Palisade Bio has raised $3.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2026.
Palisade Bio's investors include RA Capital Management, B Capital, Iterative Health, Janus Henderson Investors, Adage Capital Management.
Palisade Bio is headquartered in Carlsbad, United States.
Palisade Bio is a clinical-stage biopharmaceutical company that develops therapies for acute and chronic gastrointestinal complications.
Palisade Bio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Palisade Bio — Funding & Investors." VCBacked, March 27, 2026, https://www.vcbacked.co/company/palisade-bio. Accessed August 14, 2026.
VCBacked. (2026). Palisade Bio — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/palisade-bio
{{cite web |title=Palisade Bio — Funding & Investors |url=https://www.vcbacked.co/company/palisade-bio |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated